Groupement Des Hopitaux De L'Institut Catholique De Lille

Research conducted at Groupement Des Hopitaux De L'Institut Catholique De Lille focuses on improving outcomes for patients with rheumatoid arthritis through innovative biologic sequencing and dose‑tapering strategies. The department also explores new oral and injectable options for managing gout attacks and relieving pain in knee osteoarthritis.

• Sequential biologic therapy for rheumatoid arthritis
• Oral urate‑lowering agents in gout flare prevention
• Intra‑articular injection trials for knee osteoarthritis pain
• Head‑to‑head comparison of bimekizumab versus adalimumab in axial spondyloarthritis
• JAK inhibitor dose‑tapering in low disease activity rheumatoid arthritis

The site currently supports 28 active trials led by 24 investigators, emphasizing patient‑centered therapeutic optimization.

The rheumatology unit investigates key immune pathways to treat chronic inflammatory conditions such as atopic dermatitis and refractory gout. Studies evaluate cytokine blockade with agents targeting interleukin‑1, interleukin‑6, and dual interleukin‑17A/F inhibition.

• Anakinra versus prednisone for gout flares in chronic kidney disease
• IL‑6 inhibition in treatment‑refractory chronic inflammatory rheumatism
• Ruxolitinib cream efficacy in moderate atopic dermatitis
• Bimekizumab superiority trial in axial spondyloarthritis
• Immune system process biomarkers in rheumatic disease monitoring

These investigations aim to reduce disease activity while minimizing systemic side effects.

Oncology research at the Lille institute addresses both solid tumors and hematologic malignancies, including advanced prostate cancer staging and novel immunotherapy combinations for lymphomas. The program seeks to enhance diagnostic precision and improve progression‑free survival with targeted agents.

• Cu‑64 PSMA PET/CT imaging for pelvic lymph node detection in prostate cancer
• Isatuximab plus lenalidomide and dexamethasone with/without bortezomib in transplant‑ineligible multiple myeloma
• Odronextamab plus lenalidomide versus rituximab‑lenalidomide in relapsed/refractory follicular and marginal zone lymphoma
• Atezolizumab combined with BCG for high‑risk non‑muscle invasive bladder cancer
• Low‑dose colchicine for reduction of major vascular events in cancer patients

The clinical portfolio integrates therapeutic innovation with advanced imaging to personalize cancer care.

Trials in the neurological field target neurodegenerative and cerebrovascular disorders, with a focus on preserving cognition and reducing post‑stroke complications. One study evaluates a stimulant supplement for slowing decline in Alzheimer's disease.

• Caffeine supplementation to mitigate cognitive decline in early‑moderate Alzheimer's disease
• Anticoagulation avoidance strategies after intracerebral hemorrhage
• Management protocols for acute ischemic stroke and transient ischemic attack
• Neuroprotective effects of heart rate control in septic shock patients
• Assessment of functional outcomes following intracerebral hemorrhage

These studies aim to improve quality of life and functional recovery for patients with brain injuries.

Cardiovascular investigations explore strategies to lower mortality and prevent recurrent events in high‑risk populations, including patients with acute coronary syndromes and those experiencing septic shock. Research includes novel anticoagulation pathways and heart‑rate modulation therapies.

• Direct oral anticoagulant versus left atrial appendage closure in net clinical benefit analysis
• Landiolol infusion to reduce mortality in septic shock with hypercontractility
• Low‑dose colchicine for prevention of major vascular events
• Vitamin B3 supplementation to protect kidneys during septic shock
• Evaluation of antiplatelet regimens post‑myocardial infarction

The goal is to refine therapeutic algorithms that balance efficacy with safety in complex cardiovascular patients.

The respiratory program assesses combination inhaler therapies to enhance lung function and reduce severe cardiopulmonary outcomes in individuals with chronic obstructive pulmonary disease. Comparative trials determine the added benefit of triple bronchodilation over dual regimens.

• Triple therapy (budesonide, glycopyrronium, formoterol) versus dual bronchodilator in COPD
• Impact of inhaled corticosteroid withdrawal on exacerbation rates
• Safety profile of high‑dose bronchodilator combinations in severe COPD
• Biomarker analysis of cardiopulmonary events during inhaler therapy
• Patient‑reported outcome measures in COPD management

Outcomes focus on reducing hospitalizations and improving daily activity tolerance for respiratory patients.

Dermatologic and connective‑tissue research addresses inflammatory skin conditions and crystal‑induced arthropathies, with an emphasis on targeted topical and systemic therapies. A phase III trial evaluates a Janus kinase inhibitor cream for atopic dermatitis severity reduction.

• Ruxolitinib cream efficacy in moderate atopic dermatitis
• Tocilizumab subcutaneous administration for chondrocalcinosis
• Evaluation of IL‑17A/F dual inhibition in axial spondyloarthritis chest wall pain
• Biologic treatment sequencing for severe psoriasis associated with rheumatoid arthritis
• Safety monitoring of long‑term systemic immunosuppression in skin disease

The investigations aim to achieve rapid symptom control while preserving skin integrity and joint function.